BioLineRx Ltd. (BLRX)

0.6601 -0.0141 (-2.09%) 收市：04:00PM EDT

BioLineRx Ltd.

Modi’in Technology Park
2 HaMa’ayan Street
Hevel Modi'in 7177871
Israel
972 8 642 9100
https://www.biolinerx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 79

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA	Chief Executive Officer	598k	無	1960
Ms. Mali Zeevi CPA, CPA	Chief Financial Officer	374k	無	1976
Dr. Ella Sorani Ph.D.	Chief Development Officer	452k	無	1968
Ms. Holly W. May M.B.A.	President of BioLineRx USA	710k	無	1962
Mr. John Lacey	Head of Corporate Communications & Investor Relations	無	無	無
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B.	Head of BD & Strategic Advisor	無	無	無
Mr. Raziel Fried	Treasurer & Budgetary Control Director	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

公司管治

截至 無 止，BioLineRx Ltd. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。